Novartis has formed a collaboration with IBM Watson Health on an initiative to optimize cancer care and improve patient outcomes. The two companies will collaborate to explore development of a cognitive solution that uses real-world data and advanced analytical techniques with the aim to provide better insights on the expected outcomes of breast cancer treatment options.

This collaboration will join Novartis’ expertise in breast cancer with IBM Watson Health’s skill in data analytics and machine learning to determine which combinations and sequences may lead to the best patient outcomes. The initiative primarily will use real-world patient data.

Watson is the first commercially available cognitive computing capability. The system, delivered through the cloud, analyzes high volumes of data, understands complex questions posed in natural language, and proposes evidence-based answers. Watson continuously learns, gaining in value and knowledge over time, from previous interactions.

Source: Novartis